Vor Biopharma's Lead Hematopoietic Stem Cell Candidate Fast Tracked In US

The FDA has granted Fast Track designation to Vor Biopharma's VOR VOR33, lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for acute myeloid leukemia (AML).
VOR33 consists of CRISPR genome-edited hematopoietic stem and progenitor cells that have been engineered to lack CD33.
The Company is enrolling in its Phase 1/2a trial for AML patients and remains on track to report initial data in 1H of FY22.
Related content: Benzinga's Full FDA Calendar.
Price Action: VOR stock is 4.04% at $16.22 during the market session on the last check Thursday.